Research Trends and Regulation of CCL5 in Prostate Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006;25(3):357–371.
   PubMed Web of Science ®Google Scholar
• Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr. 2013;23(1):77–91.
   PubMed Web of Science ®Google Scholar
• Huang R, Wang S, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling. Cell Death Dis. 2020;11(4):234.
   PubMed Web of Science ®Google Scholar
• Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 2007;26(3–4):401–420.
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702.
   PubMed Web of Science ®Google Scholar
• Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147(3):577–594.e571.
   PubMed Web of Science ®Google Scholar
• Walz DA, Wu VY, de Lamo R, Dene H, McCoy LE. Primary structure of human platelet factor 4. Thromb Res. 1977;11(6):893–898.
   PubMed Web of Science ®Google Scholar
• Gueron G, De Siervi A, Vazquez E. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis. 2012;15(3):213–221.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunology Res. 2014;2(12):1125–1131.
   PubMed Web of Science ®Google Scholar
• Christopherson K, Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells. 2001;19(5):388–396.
   PubMed Web of Science ®Google Scholar
• Maolake A, Izumi K, Shigehara K, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. Oncotarget. 2017;8(6):9739–9751.
   PubMedGoogle Scholar
• Sung SY, Hsieh CL, Law A, et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008;68(23):9996–10003.
   PubMed Web of Science ®Google Scholar
• Kato T, Fujita Y, Nakane K, et al. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine. 2013;64(1):251–257.
   PubMed Web of Science ®Google Scholar
• Schall TJ, Jongstra J, Dyer BJ, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988;141(3):1018–1025.
   PubMed Web of Science ®Google Scholar
• König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58(2):121–129.
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271–285.
   PubMed Web of Science ®Google Scholar
• Velasco-Velazquez M, Xolalpa W, Pestell RG. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets. 2014;18(11):1265–1275.
   PubMed Web of Science ®Google Scholar
• Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17(12):1439–1460.
   PubMed Web of Science ®Google Scholar
• Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. The Prostate. 2006;66(2):124–134.
   PubMed Web of Science ®Google Scholar
• Colombatti M, Grasso S, Porzia A, et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One. 2009;4(2):e4608.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014;2014:292376.
   PubMed Web of Science ®Google Scholar
• Barcelos LS, Coelho AM, Russo RC, et al. Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. Microvasc Res. 2009;78(2):148–154.
   PubMed Web of Science ®Google Scholar
• Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003;44(2):590–593.
   PubMed Web of Science ®Google Scholar
• Tang S, Xiang T, Huang S, et al. Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling. Cancer Lett. 2016;376(1):137–147.
   PubMed Web of Science ®Google Scholar
• Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res. 2005;11(23):8358–8363.
   PubMed Web of Science ®Google Scholar
• Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418(6900):823.
   PubMed Web of Science ®Google Scholar
• Meehan WJ, Samant RS, Hopper JE, et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem. 2004;279(2):1562–1569.
   PubMed Web of Science ®Google Scholar
• Horak CE, Mendoza A, Vega-Valle E, et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res. 2007;67(24):11751–11759.
   PubMed Web of Science ®Google Scholar
• Sahni S, Bae DH, Lane DJ, et al. The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. J Biol Chem. 2014;289(14):9692–9709.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69(18):7135–7139.
   PubMed Web of Science ®Google Scholar
• Stuelten CH, Parent CA, Montell DJ. Cell motility in cancer invasion and metastasis: insights from simple model organisms. Nat Rev Cancer. 2018;18(5):296–312.
   PubMed Web of Science ®Google Scholar
• Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704–1709.
   PubMed Web of Science ®Google Scholar
• Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62(4):1093–1102.
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol. 2002;32(2):404–412.
   PubMed Web of Science ®Google Scholar
• Long H, Xiang T, Qi W, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget. 2015;6(8):5846–5859.
   PubMedGoogle Scholar
• Huang CY, Fong YC, Lee CY, et al. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 2009;77(5):794–803.
   PubMed Web of Science ®Google Scholar
• Long H, Xie R, Xiang T, et al. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells. 2012;30(10):2309–2319.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–563.
   PubMed Web of Science ®Google Scholar
• Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851(6):882–897.
   PubMed Web of Science ®Google Scholar
• Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res. 2012;72(2):379–386.
   PubMed Web of Science ®Google Scholar
• Kim JE, Kim HS, Shin YJ, et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med. 2008;40(5):514–522.
   PubMed Web of Science ®Google Scholar
• Wang SW, Wu HH, Liu SC, et al. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One. 2012;7(4):e35101.
   PubMed Web of Science ®Google Scholar
• Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 2015;75(11):2151–2158.
   PubMed Web of Science ®Google Scholar
• Yeh CR, Slavin S, Da J, et al. Estrogen receptor alpha in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. Mol Cancer. 2016;15:7.
   PubMed Web of Science ®Google Scholar
• Zhao R, Bei X, Yang B, et al. Endothelial cells promote metastasis of prostate cancer by enhancing autophagy. J Exp Clin Cancer Res. 2018;37(1):221.
   PubMedGoogle Scholar
• Urata S, Izumi K, Hiratsuka K, et al. C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. Cancer Sci. 2018;109(3):724–731.
   PubMed Web of Science ®Google Scholar
• Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583–4591.
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485–497.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–323.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60(6):273–276.
   PubMed Web of Science ®Google Scholar
• Tsuyada A, Chow A, Wu J, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012;72(11):2768–2779.
   PubMed Web of Science ®Google Scholar
• Zou W, Wicha MS. Chemokines and cellular plasticity of ovarian cancer stem cells. Oncoscience. 2015;2(7):615–616.
   PubMedGoogle Scholar
• Borghese C, Cattaruzza L, Pivetta E, et al. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. J Cell Biochem. 2013;114(5):1135–1144.
   PubMed Web of Science ®Google Scholar
• Luo J, Ok Lee S, Liang L, et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. 2014;33(21):2768–2778.
   PubMed Web of Science ®Google Scholar
• Luo J, Lee SO, Cui Y, Yang R, Li L, Chang C. Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2alpha/androgen receptor signals. Oncotarget. 2015;6(29):27555–27565.
   PubMedGoogle Scholar
• Chuang HC, Chou MH, Chien CY, Chuang JH, Liu YL. Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells. Oral Oncol. 2018;86:141–149.
   PubMed Web of Science ®Google Scholar
• Zhou B, Sun C, Li N, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J Oncol. 2016;48(5):2087–2097.
   PubMed Web of Science ®Google Scholar
• Yi EH, Lee CS, Lee JK, et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 2013;11(1):31–42.
   PubMed Web of Science ®Google Scholar
• Xiang P, Jin S, Yang Y, et al. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling. The Prostate. 2019;79(9):1018–1031.
   PubMed Web of Science ®Google Scholar
• Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prevent. 2011;20(7):1543–1551.
   PubMed Web of Science ®Google Scholar
• Sugasawa H, Ichikura T, Tsujimoto H, et al. Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol. 2008;97(5):445–450.
   PubMed Web of Science ®Google Scholar
• Sicoli D, Jiao X, Ju X, et al. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res. 2014;74(23):7103–7114.
   PubMed Web of Science ®Google Scholar
• Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer. 2010;10:165.
   PubMed Web of Science ®Google Scholar
• Tsaur I, Noack A, Makarevic J, et al. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: a Pilot Study. Cancer Res Treatment. 2015;47(2):306–312.
   Google Scholar
• Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. The Prostate. 2013;73(6):573–581.
   PubMed Web of Science ®Google Scholar
• Kidd LR, Jones DZ, Rogers EN, et al. Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hered Cancer Clin Pract. 2012;10(1):16.
   PubMedGoogle Scholar
• Zheng Y, Han GW, Abagyan R, et al. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV. Immunity. 2017;46(6):1005–1017.e1005.
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Berthel A, et al. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016;29(4):587–601.
   PubMed Web of Science ®Google Scholar
• Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49(12):4911–4919.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008;52(3):858–865.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ. Novel compounds for the treatment of HIV type-1 infection. Antivir Chem Chemother. 2009;19(5):189–200.
   PubMedGoogle Scholar
• Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A. 1999;96(10):5698–5703.
   PubMed Web of Science ®Google Scholar
• Maeda K, Das D, Nakata H, Mitsuya H. CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs. 2012;17(2):135–145.
   PubMed Web of Science ®Google Scholar
• Haney KM, Zhang F, Arnatt CK, et al. The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents. Bioorg Med Chem Lett. 2011;21(18):5159–5163.
   PubMed Web of Science ®Google Scholar
• Mack M, Cihak J, Simonis C, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol. 2001;166(7):4697–4704.
   PubMed Web of Science ®Google Scholar
• Sutton A, Friand V, Papy-Garcia D, et al. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther. 2007;6(11):2948–2958.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Y, Zhu S, et al. DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway. Front Pharmacol. 2018;9:1450.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Casagrande N. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer. Int J Mol Sci. 2018;19:5.
   Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721–4732.
   PubMed Web of Science ®Google Scholar
• Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015;9:5447–5468.
   PubMed Web of Science ®Google Scholar
• Jayasuriya H, Herath KB, Ondeyka JG, et al. Isolation and structure of antagonists of chemokine receptor (CCR5). J Nat Prod. 2004;67(6):1036–1038.
   PubMed Web of Science ®Google Scholar
• Zhang X, Haney KM, Richardson AC, et al. Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorg Med Chem Lett. 2010;20(15):4627–4630.
   PubMed Web of Science ®Google Scholar
• Xu GG, Zaidi SA, Zhang F, et al. Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents. Bioorg Med Chem Lett. 2015;25(17):3721–3725.
   PubMed Web of Science ®Google Scholar
• Zhang F, Arnatt CK, Haney KM, et al. Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents. Eur J Med Chem. 2012;55:395–408.
   PubMed Web of Science ®Google Scholar
• Khan GJ, Rizwan M, Abbas M, et al. Pharmacological effects and potential therapeutic targets of DT-13. Biomed Pharmacother. 2018;97:255–263.
   PubMed Web of Science ®Google Scholar
• Lin SS, Fan W, Sun L, et al. The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis. Chin J Nat Med. 2014;12(11):833–840.
   PubMed Web of Science ®Google Scholar
• Ren-Ping Z, Sen-Sen L, Yuan ST, et al. DT-13, a saponin of dwarf lilyturf tuber, exhibits anti-cancer activity by down-regulating C-C chemokine receptor type 5 and vascular endothelial growth factor in MDA-MB-435 cells. Chin J Nat Med. 2014;12(1):24–29.
   PubMed Web of Science ®Google Scholar
• Li H, Sun L, Li H, et al. DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells. Cell Death Dis. 2017;8(5):e2810.
   PubMedGoogle Scholar
• Yu XW, Lin S, Du HZ, et al. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo. Oncotarget. 2016;7(22):32990–33003.
   PubMedGoogle Scholar
• Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol. 2007;3(3):164–170.
   PubMedGoogle Scholar
• Fessele S, Maier H, Zischek C, Nelson PJ, Werner T. Regulatory context is a crucial part of gene function. Trends Genetics. 2002;18(2):60–63.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar